Keymed Biosciences Inc. Announces Completion of Ouro Medicines Equity Disposal and Major Drug Development Updates
Key Points Investors Must Know
- Completion of Major Transaction: Keymed Biosciences Inc. has completed the disposal of its minority equity interest in Ouro Medicines via its wholly-owned subsidiary iBridge HK.
- Significant Cash Inflow: Keymed received an upfront payment of approximately US\$257 million from the transaction.
- Further Potential Earnings: The company is entitled to milestone payments of up to US\$70 million related to the merger. In addition, milestone payments of up to US\$610 million remain active under an exclusive license agreement, along with tiered royalties on net sales.
- Strategic Collaboration: Under the arrangement, Gilead Sciences acquired all equity interests in Ouro Medicines for US\$1,675 million upfront and up to US\$500 million in milestone payments, which will be split equally with Lakefront Biotherapeutics NV (formerly Galapagos).
- Ongoing Drug Development: The exclusive license agreement between Keymed and Ouro Medicines remains effective post-acquisition. Development and commercialization activities for CM336/OM336 will be led by Gilead and Lakefront, with Gilead retaining global commercialization rights (excluding Greater China).
- CM336/OM336 Drug Profile: CM336/OM336 is an innovative bispecific antibody for severe antibody-mediated autoimmune diseases. It has received Fast Track Designation and Orphan Drug Designation from the US FDA for two indications: autoimmune hemolytic anemia (AIHA) and primary immune thrombocytopenia (ITP).
- Clinical Results: The drug demonstrated outstanding efficacy in early clinical studies, including rapid and sustained treatment-free remission in patients with AIHA. Results have been published in the New England Journal of Medicine.
- Future Outlook: The drug is expected to enter registrational studies in 2027, and additional indication development plans will be updated by Gilead and Lakefront.
Details That May Affect Share Value
- Large Cash Injection: The receipt of US\$257 million upfront is a significant boost to Keymed’s financial position, providing capital for further R&D and operations.
- Potential for Additional Earnings: The company stands to gain up to US\$70 million in merger milestone payments and up to US\$610 million in additional milestones under the license agreement, plus ongoing royalties. These future payments are contingent on clinical and commercial success.
- Ongoing Drug Development Risk: Despite promising clinical results and FDA designations, Keymed cautions that there is no assurance CM336/OM336 will ultimately be successfully developed, launched, or commercialized.
- Strategic Partnerships: Collaboration with Gilead and Lakefront enhances the prospects for CM336/OM336’s development and commercialization globally, potentially accelerating the drug’s path to market.
- Regulatory Milestones: FDA Fast Track and Orphan Drug Designations increase visibility and potential for expedited review, which could positively impact future revenue and share price if successful.
- Publication in Top Journal: Clinical results published in the New England Journal of Medicine lend credibility and could attract further investor interest.
- Risk Warning: The company advises shareholders and investors to exercise caution, as there is no guarantee of drug commercialization success.
Comprehensive Transaction Overview
Keymed Biosciences Inc. has successfully completed the disposal of its minority equity stake in Ouro Medicines, a move first announced in March and April 2026. The transaction involved Gilead Sciences acquiring all equity interests in Ouro Medicines for US\$1,675 million upfront and up to US\$500 million in milestone payments. These amounts are to be split equally between Gilead and Lakefront Biotherapeutics NV (formerly Galapagos). As a minority shareholder, Keymed received US\$257 million upfront and is eligible for up to US\$70 million in milestone payments from the transaction.
Importantly, a previously signed exclusive license agreement between Keymed and Ouro Medicines remains effective. This agreement entitles Keymed to milestone payments of up to US\$610 million and tiered royalties on future net sales, now to be fulfilled by Gilead and Lakefront. Lakefront has acquired most of Ouro Medicines’ team and operational assets and will collaborate with Gilead on the development of CM336/OM336. Lakefront will handle ongoing and future Phase I/II studies, while Gilead will lead registrational and late-stage studies and retain commercialization rights outside Greater China.
About CM336/OM336
CM336/OM336 is an innovative TCE bispecific antibody developed by Keymed. The drug targets BCMA and CD3, recruiting T cells to eliminate pathogenic B cells and plasma cells, offering a potential paradigm shift from chronic management to durable immune reset in severe autoimmune diseases. It has received Fast Track and Orphan Drug Designations from the US FDA for AIHA and ITP. In clinical studies, it demonstrated impressive efficacy, with patients achieving rapid and sustained remission without severe adverse events (CRS or ICANS). The drug is expected to enter registrational studies in 2027, with further indication development to be updated.
Risk Warning
While the transaction and clinical progress are positive, Keymed has emphasized that there is no assurance CM336/OM336 will be successfully developed, launched, or commercialized. Shareholders and prospective investors should exercise caution when dealing in company shares.
Board Information
The Board of Directors of Keymed Biosciences Inc. comprises Dr. Bo Chen (Chairman), Dr. Changyu Wang, Dr. Gang Xu (Executive Directors), Mr. Qi Chen, Dr. Min Chuan Wang, Mr. Yilun Liu (Non-executive Directors), and Prof. Xiao-Fan Wang, Prof. Yang Ke, Mr. Cheuk Kin Stephen Law (Independent Non-executive Directors).
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. The information is based on official company announcements. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions.
康諾生物科技完成Ouro Medicines股份出售及藥物研發最新消息
投資者必須注意的重點
- 重大交易完成：康諾生物科技透過全資子公司iBridge HK完成Ouro Medicines少數股權出售。
- 巨額現金流入：公司已收到約 2.57億美元的交易首期款項。
- 額外收入潛力：公司有權獲得最多 7,000萬美元的里程碑付款，以及根據專屬授權協議，最高 6.1億美元的里程碑付款及分級銷售權利金。
- 策略合作：Gilead Sciences以16.75億美元首期款項及最高5億美元里程碑付款收購Ouro Medicines全部股權，款項與Lakefront Biotherapeutics NV（前稱Galapagos）平分。
- 藥物研發持續：康諾與Ouro Medicines的專屬授權協議繼續生效，Gilead與Lakefront負責CM336/OM336的研發及商品化。
- CM336/OM336藥物簡介：該藥為創新雙特異性抗體，獲美國FDA 快速通道及 孤兒藥指定，用於自身免疫性溶血性貧血（AIHA）及原發性免疫性血小板減少症（ITP）。
- 臨床成果：早期臨床研究顯示療效突出，包括AIHA患者快速且持續的無藥物緩解，結果已刊於 新英格蘭醫學期刊。
- 未來展望：預計2027年進入註冊性研究，更多適應症發展計劃將由Gilead/Lakefront更新。
可能影響股價的詳情
- 巨額現金注入：2.57億美元首期款項顯著提升公司財務狀況，有助研發及營運。
- 額外收入潛力：公司可再獲最多7,000萬美元及6.1億美元里程碑付款，另有持續銷售權利金，視乎臨床及商業進展。
- 藥物開發風險：儘管臨床表現理想及獲FDA認可，公司提醒未必能成功開發及商品化CM336/OM336。
- 策略合作提升前景：與Gilead及Lakefront合作，有望加速全球藥物發展及商品化。
- 監管里程碑：FDA快速通道及孤兒藥指定提高審批機會，若有成功可大幅改善收入及股價。
- 頂尖期刊發表：臨床結果於新英格蘭醫學期刊刊登，增強信譽，或吸引更多投資者。
- 風險提示：公司提醒股東及投資者需謹慎，無法保證藥物最終成功商品化。
詳細交易概述
康諾生物科技已完成Ouro Medicines少數股權出售。Gilead Sciences以16.75億美元首期款項及最高5億美元里程碑付款收購Ouro Medicines全部股權，與Lakefront平分。康諾作為少數股東，收到2.57億美元首期款項，並有資格獲得最多7,000萬美元里程碑付款。
專屬授權協議仍然生效，康諾有權獲得最高6.1億美元里程碑付款及分級銷售權利金，現由Gilead及Lakefront履行。Lakefront獲得大部分Ouro Medicines團隊及資產，將與Gilead合作CM336/OM336研發。Lakefront負責第一及第二期臨床研究，Gilead則主導註冊及後期研究，並擁有全球（大中華除外）商品化權利。
CM336/OM336藥物介紹
CM336/OM336由康諾自主研發，屬創新雙特異性抗體，標靶BCMA及CD3，能招募T細胞消滅病原B細胞及漿細胞，推動慢性病管理至持久免疫重置。獲FDA快速通道及孤兒藥指定，臨床研究顯示療效卓越，患者快速達到持續無藥物緩解，無嚴重副作用。預計2027年進入註冊性研究。
風險提示
雖然交易及藥物進展正面，公司強調無法保證CM336/OM336最終能成功開發及商品化。股東及投資者需謹慎操作。
董事會資訊
康諾生物科技董事會成員包括：董事長陳波博士，執行董事王昌宇博士、徐剛博士，非執行董事陳琪先生、王敏川博士、劉怡倫先生，獨立非執行董事王小凡教授、柯揚教授、羅卓健先生。
免責聲明：
本文僅供參考，不構成投資建議。資料來源於公司公告，投資者請自行做足功課及諮詢專業人士後才作投資決定。
